Curasight A/S
Developing uPAR theranostics to precisely diagnose and treat cancers like brain and prostate.
CURAS | SPGR
Overview
Corporate Details
- ISIN(s):
- DK0061295797 (+3 more)
- LEI:
- 984500C9E3ADR98F1070
- Country:
- Denmark
- Address:
- Ole Maaløes Vej 3, 2200 København N
- Website:
- https://www.curasight.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Curasight A/S is a clinical-stage biotechnology company developing a more gentle and efficient approach to cancer care through its proprietary uPAR Theranostics platform. This technology targets the urokinase-type plasminogen activator receptor (uPAR), a biomarker expressed in numerous cancers. The platform integrates precise diagnostics using the uTRACE® imaging agent with targeted radionuclide therapy delivered by the uTREAT® agent. This integrated 'theranostics' approach aims to improve treatment outcomes by accurately identifying and treating cancer while minimizing radiation damage to healthy tissue. The company's clinical development focuses on several indications, including brain and prostate cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Curasight A/S filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Curasight A/S
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Curasight A/S via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
